PGNX
Progenics Pharmaceuticals Inc
PGNX
PGNX
Delisted
PGNX was delisted on the 19th of June, 2020.
135 hedge funds and large institutions have $343M invested in Progenics Pharmaceuticals Inc in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 49 increasing their positions, 44 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
135
Holders Change
-7
Holders Change %
-4.93%
% of All Funds
2.97%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
49
Reduced
44
Closed
16
Calls
$2.26M
Puts
$993K
Net Calls
+$1.27M
Net Calls Change
-$265K
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
$24.5M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
$37.2M |
| 3 |
BC
Broadfin Capital
New York
|
$8.01M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
$28.6M |
| 5 |
Citigroup
New York
|
$1.28M |
